Trial · NCT07299149
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate，ORR | up to the end of 6 cycles of treatment(each cycle is 28 days)] | Defined as the proportion of patients with complete or partial response as assessed by response to induction therapy |
| Secondary | Complete response rate，CRR | up to the end of 6 cycles of treatment(each cycle is 28 days) | defined as the proportion of patients with complete response as assessed by response to induction therapy. |
| Secondary | Best overall response rate (ORR) and complete response rate (CRR) during treatment | Up to the end of 6 cycles of treatment(each cycle is 28 days) | defined as the proportion of patients with best response as assessed in the induction therapy. |
| Secondary | CRR and ORR at end of treatment | at the end of Cycle 24 (each cycle is 28 days) | Defined as the proportion of patients with complete response, and complete or partial response as assessed by response to the end of treatment(induction + maintenance therapy) |
| Secondary | Progression-free survival (PFS) | up to 5 years | The time from the enrollment of a subject to the occurrence of (in any way) progression of disease or Death for any reason. patients with indeterminate recurrence or Death at the last follow-up, defined as the date of the last Investigation |
| Secondary | Duration of response (DOR) | up to 5 years | defined as the time from the first treatment response (including complete response and partial response) to the last assessment of response. |
| Secondary | Time to response (TTR) | at the end of Cycle 24 (each cycle is 28 days) | |
| Secondary | 2-year overall survival (OS) rate | up to 2 years | The time from subject enrollment to Death caused by any reason. for patients lost to follow-up, the time of the last follow-up; for patients still alive at the end of study, the date of the end of follow-up |
| Secondary | Proportion of patients with progression of disease within 24 months (POD24) | Up to the end of 2 years (each cycle is 28 days) | |
| Secondary | The safety | up to 5 years | Incidence of adverse events, serious adverse events and significant adverse event |
| Other | Minimal residual disease (MRD) monitoring | Up to the end of 24 cycles of treatment(each cycle is 28 days) | |
| Other | Circulating tumor DNA (ctDNA) analysis via next-generation sequencing (NGS) | Up to the end of 24 cycles of treatment(each cycle is 28 days) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07299149/registered